INSTALL DOSE CALCULATOR
Calculator Go back to the ENVARSUS® PA website
EN FR

AVAILABLE ON ALL PROVINCIAL FORMULARIES!

(Restrictions may apply)*,1

Consider PrENVARSUS® PA for your kidney and liver transplant patients2

ENVARSUS® PA (tacrolimus prolonged-release tablets) is indicated for the prophylaxis of organ rejection in adult allogenic kidney or liver transplant patients in combination with other immunosuppressants.

Demonstrated incidence of predefined potentially clinically significant laboratory tests within 12 months after randomization

A prolonged-release tacrolimus formulation that’s unique to ENVARSUS® PA†,3

The ENVARSUS® PA formulation prolongs the absorption and increases the delivery of tacrolimus into the blood when compared to other tacrolimus formulations.2

ENVARSUS® PA is NOT interchangeable or substitutable on an equal dose-by-dose basis with other existing tacrolimus-containing products (immediate- or extended-release capsules).

Learn more

Until 2029, ENVARSUS® PA is a patent-protected tacrolimus prolonged-release formulation.‡,4

The PalSupport Patient Support Program offers a variety of services for your patients on ENVARSUS® PA, including:

  • Reimbursement navigation
  • Nurse case managers
  • Specialty pharmacy
  • Therapy management tools

For more information about the PalSupport Patient Support Program, email PalSupport@bayshore.ca or call 1-877-261-4586.

DETERMINE YOUR PATIENT'S DOSE

*ENVARSUS® PA is eligible for formulary coverage in Alberta (under the Specialized High-Cost Drug Program), British Columbia (through BC Transplant), New Brunswick, Newfoundland and Labrador (through Eastern Health Pharmacy Services), Prince Edward Island, and Quebec,§ with exception status in Manitoba, Saskatchewan, and Nova Scotia, and with limited use status in Ontario.
†Please see the Product Monograph for complete dosing and administration information.
‡Clinical significance is unknown.
§As part of the RAMQ, the official mark of the Régie de l’assurance maladie du Québec.